Advertisement

Topics

PARI Pharma Development Featuring eFlow Technology for Bronchiolitis Obliterans Syndrome (BOS) Is Licensed To Breath Therapeutics Holding BV

20:00 EDT 19 Mar 2017 | BioSpace

  Life Sciences Jobs   ...

Original Article: PARI Pharma Development Featuring eFlow Technology for Bronchiolitis Obliterans Syndrome (BOS) Is Licensed To Breath Therapeutics Holding BV

NEXT ARTICLE

More From BioPortfolio on "PARI Pharma Development Featuring eFlow Technology for Bronchiolitis Obliterans Syndrome (BOS) Is Licensed To Breath Therapeutics Holding BV"

Quick Search
Advertisement